Brought to you by 
Tercica completes $52.9mm initial public offering
23 Apr 2004
Executive Summary
Tercica (focuses on endocrine system disorders) has sold 6.3mm common shares (including the overallotment) at $9 each, bringing in net proceeds of $52.9mm with its initial public offering. The company had first filed to bring in up to $86.25mm with the sale of 5mm shares priced between $14-16 apiece, then lowered the price to $11-13 per share a few months later.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tercica completes $52.9mm initial public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice